Human PapillomaVirus Vaccine Uptake: Attitudes and Practices Among Moroccan Physicians
Aicha Yacouti,Rachida Baddou,Hiba Bourissi,Sana Ez-zaouy,Hafssa Amayou,Khadija Elmalki,Abdeljalil El Got,Abdellatif Benider,Samira Zoa Assoumou,Mustapha Mouallif
DOI: https://doi.org/10.1007/s13187-024-02505-x
2024-10-18
Journal of Cancer Education
Abstract:In Morocco, cervical cancer is a serious public health problem with an estimated number of 2165 new cases and 1199 deaths in 2020. The human papillomavirus (HPV) vaccine has been available in Morocco since 2008. Few data are available on physicians' practices and attitudes toward HPV vaccine. Hence, this study aims to evaluate physicians' awareness and practice towards HPV vaccine and to highlight the main factors affecting physicians' recommendation of this vaccine in Morocco. We have carried out a structured interviewer-administered questionnaire with 500 physicians in different Moroccan regions between March 2019 and March 2020. This study showed an insufficient level of awareness of the two most common types of HPV associated with cervical cancer (36.6%). The rate of HPV vaccine recommendation did not exceed 16.6%. However, more than 63% of participants who were aware of HPV vaccine were willing to recommend it for their future eligible patients. Age ( p value < 0.01), sector of activity ( p value < 0.01), awareness of the two most common types of HPV associated with genital warts ( p value = 0.02), of the vaccine schedules ( p value = 0.03), and of the commercial name of this vaccine ( p value < 0.01), were significant factors influencing physicians' recommendation of HPV vaccine. Our results showed that, older age (above 51 years old) was associated with negative attitude towards the recommendation of this vaccine (OR: 0.17, 0.06–0.46 CI 95%). Practice in public sector was positively associated with recommendation of HPV vaccine (OR: 7.54, 3.38–16.80 CI 95%). Who were aware of the two most common types of HPV associated with genital warts were more likely to recommend HPV vaccine (OR: 3.36, 1.31–8.65 CI 95%). In the same line, participants, who were also more likely to recommend the vaccine, were those who were aware of HPV vaccine schedules (OR: 6.07, 3.51–10.50 IC 95%); participants who were aware of the commercial name of the HPV vaccine were more likely to recommend the vaccine (OR: 10.04, 5.02–20.09 IC 95%). Indeed, raising physicians' awareness is urgently needed to improve HPV vaccine coverage within Moroccan population.
oncology,public, environmental & occupational health,education, scientific disciplines